Abstract:e13097 Background: Triple negative breast cancer (TNBC) is an orphan disease that attacks > 46,000 US women every year. TNBC recurs after standard-of-care surgery, chemotherapy and radiation, killing half its victims within 4 years. Poly(ADP-ribose) polymerase (PARP) inhibitors, topoisomerase inhibitors, immune checkpoint inhibitors, and antibody-drug conjugates extend the survival of a fraction of TNBC patients for a few months. Thus, TNBC shows a critical need for molecularly-targeted therapy. Most TNBC cells show high microRNA 21 (miR-21), identical in humans and mice, which decreases tumor suppressor proteins that keep cell growth in check. Hypothesis: Short anti-miR-21 RNA analogs conjugated to a receptor ligand will direct TNBC cell uptake and slow the growth of TNBC orthotopic allografts with immune activation and minimal toxicity. Methods: We designed an anti-miR-21 RNA analog using aminomethyl bridged nucleic acid (BNA), exhibiting low toxicity, and serum stability. We lipofected a concentration ramp of the anti-miR-21 RNA analog into human TNBC cell lines (MDA-MB-231, MDA-MB-157, MDA-MB-436, MDA-MB-468, BT-20, BT-549, HCC1806, HCC1937, HCC1806) representing a spectrum of TNBC subtypes, then measured proliferation and biochemical markers. We also conjugated a peptide analog for endocytosis by the insulin-like growth factor 1 receptor (IGF1R), overexpressed in most TNBC lesions. The peptide ligand for IGF1R provides a unique strategy for delivering the anti-miR-21 RNA analog preferentially into TNBC cells. We administered 5 mg/kg of the anti-miR-21 RNA-peptide analog in sterile saline intraperitoneally twice a week for 14 days into immunocompetent female Balb/c mice bearing syngeneic EMT6 TNBC tumors in their mammary fat pads. Results: The anti-miR-21 RNA analog slowed proliferation, increased apoptosis, elevated tumor suppressor proteins, and suppressed immune checkpoint gene expression in multiple human TNBC lines. IC50 for inhibiting cell proliferation correlated with miR-21 copies/cell in 7 TNBC cell lines, but not in the non-tumorigenic breast epithelial cell line MCF-10A. The anti-miR-21 RNA-peptide analog stopped orthotopic TNBC allograft growth in syngeneic immunocompetent female Balb/c mice during 14 days of therapy, with apparent safety. Conclusions: This strategy optimizes cancer cell-specific delivery to block proliferation and immune checkpoints. The results support further preclinical proof-of-concept studies to enable an eIND submission for the anti-miR-21 RNA-peptide analog.

Chimeric MicroRNA-1291 Biosynthesized Efficiently in Escherichia Coli is Effective to Reduce Target Gene Expression in Human Carcinoma Cells and Improve Chemosensitivity.

Bioengineering Novel Chimeric Microrna-34A for Prodrug Cancer Therapy: High-Yield Expression and Purification, and Structural and Functional Characterization.

Fully‐humanized Bioengineered Mir‐1291 Modulates Key Nutrient Transport and Metabolism to Exert Synergistic Anticancer Effects with Chemotherapeutics

Let the Cells Do the Work: Production of Novel Recombinant Pre‐mirnas in E. Coli As Therapeutic Agents

Synthetic Circular Multi-Mir Sponge Simultaneously Inhibits Mir-21 and Mir-93 in Esophageal Carcinoma

Bioengineered Microrna-1291 Effects on Pancreatic Cancer Cell Proliferation and Xenograft Tumor Growth.

Rapid Production of Novel Pre-Microrna Agent Hsa-Mir-27b in Escherichia Coli Using Recombinant RNA Technology for Functional Studies in Mammalian Cells.

Bioengineered Mir‐328‐3p Modulates SLC2A1/GLUT1‐mediated Glucose Uptake and Metabolism to Exert Synergistic Antiproliferative Effects with Chemotherapeutics

Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models.

Bioengineered Mir-328-3p Modulates GLUT1-mediated Glucose Uptake and Metabolism to Exert Synergistic Antiproliferative Effects with Chemotherapeutics

Methylation of Mir-129-5p CpG Island Modulates Multi-Drug Resistance in Gastric Cancer by Targeting ABC Transporters.

Bioengineered Mir-27B-3p and Mir-328-3p Modulate Drug Metabolism and Disposition Via the Regulation of Target ADME Gene Expression.

A General Approach to High-Yield Biosynthesis of Chimeric Rnas Bearing Various Types of Functional Small Rnas for Broad Applications

Therapeutic Delivery of Mir-29B Enhances Radiosensitivity in Cervical Cancer.

A Novel Bioengineered MicroRNA-127 Prodrug Suppresses The Growth And Metastatic Potential Of Triple Negative Breast Cancer Cells.

Mir-133B Down-Regulates ABCC1 and Enhances the Sensitivity of CRC to Anti-Tumor Drugs

Adenovirus-mediated Shrnas for Co-Repression of Mir-221 and Mir-222 Expression and Function in Glioblastoma Cells.

In vivo fermentation production of humanized noncoding RNAs carrying payload miRNAs for targeted anticancer therapy

Regulation of microRNA-129-2 expression by cytosine-phosphoric acid-guanine motif island methylation and its effect on the proliferation and colony formation in renal cell carcinoma

Effect of microRNA-21 blockade in human triple negative breast cancer allografts on progression and immune checkpoint proteins.

A novel miR-1291-ERRα-CPT1C axis modulates tumor cell proliferation, metabolism and tumorigenesis